Late-onset neutropenia after anti-CD20 therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG antibody-associated disease: A prospective study

Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases

(2020) J. Rigal et al.   Multiple Sclerosis and Related Disorders

Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab

(2020) Michael Auer et al.   Multiple Sclerosis and Related Disorders

Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis

(2019) Bruce A. Cohen   NEUROLOGY

Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature

(2019) Chiara Zanetta et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders

(2018) J. Ciron et al.   REVUE NEUROLOGIQUE

Severe neutropenia after rituximab-treatment of multiple sclerosis

(2018) Eero Rissanen et al.   Multiple Sclerosis and Related Disorders

Late-onset neutropenia during long-term rituximab therapy in neuromyelitis optica

(2013) Annika Plate et al.   Multiple Sclerosis and Related Disorders

Neutropenia after rituximab treatment

(2011) Ofir Wolach et al.   CURRENT OPINION IN HEMATOLOGY